Cargando…
Bortezomib-Containing Multimodality Treatment for Antibody-Mediated Rejection with Anti-HLA and Anti-AT1R Antibodies after Kidney Transplantation
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Yonsei University College of Medicine
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368161/ https://www.ncbi.nlm.nih.gov/pubmed/28332381 http://dx.doi.org/10.3349/ymj.2017.58.3.679 |
| _version_ | 1782517872768057344 |
|---|---|
| author | Iesari, Samuele Lai, Quirino Favi, Evaldo Pisani, Francesco |
| author_facet | Iesari, Samuele Lai, Quirino Favi, Evaldo Pisani, Francesco |
| author_sort | Iesari, Samuele |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5368161 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Yonsei University College of Medicine |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-53681612017-05-01 Bortezomib-Containing Multimodality Treatment for Antibody-Mediated Rejection with Anti-HLA and Anti-AT1R Antibodies after Kidney Transplantation Iesari, Samuele Lai, Quirino Favi, Evaldo Pisani, Francesco Yonsei Med J Letter to the Editor Yonsei University College of Medicine 2017-05-01 2017-03-15 /pmc/articles/PMC5368161/ /pubmed/28332381 http://dx.doi.org/10.3349/ymj.2017.58.3.679 Text en © Copyright: Yonsei University College of Medicine 2017 http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letter to the Editor Iesari, Samuele Lai, Quirino Favi, Evaldo Pisani, Francesco Bortezomib-Containing Multimodality Treatment for Antibody-Mediated Rejection with Anti-HLA and Anti-AT1R Antibodies after Kidney Transplantation |
| title | Bortezomib-Containing Multimodality Treatment for Antibody-Mediated Rejection with Anti-HLA and Anti-AT1R Antibodies after Kidney Transplantation |
| title_full | Bortezomib-Containing Multimodality Treatment for Antibody-Mediated Rejection with Anti-HLA and Anti-AT1R Antibodies after Kidney Transplantation |
| title_fullStr | Bortezomib-Containing Multimodality Treatment for Antibody-Mediated Rejection with Anti-HLA and Anti-AT1R Antibodies after Kidney Transplantation |
| title_full_unstemmed | Bortezomib-Containing Multimodality Treatment for Antibody-Mediated Rejection with Anti-HLA and Anti-AT1R Antibodies after Kidney Transplantation |
| title_short | Bortezomib-Containing Multimodality Treatment for Antibody-Mediated Rejection with Anti-HLA and Anti-AT1R Antibodies after Kidney Transplantation |
| title_sort | bortezomib-containing multimodality treatment for antibody-mediated rejection with anti-hla and anti-at1r antibodies after kidney transplantation |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368161/ https://www.ncbi.nlm.nih.gov/pubmed/28332381 http://dx.doi.org/10.3349/ymj.2017.58.3.679 |
| work_keys_str_mv | AT iesarisamuele bortezomibcontainingmultimodalitytreatmentforantibodymediatedrejectionwithantihlaandantiat1rantibodiesafterkidneytransplantation AT laiquirino bortezomibcontainingmultimodalitytreatmentforantibodymediatedrejectionwithantihlaandantiat1rantibodiesafterkidneytransplantation AT favievaldo bortezomibcontainingmultimodalitytreatmentforantibodymediatedrejectionwithantihlaandantiat1rantibodiesafterkidneytransplantation AT pisanifrancesco bortezomibcontainingmultimodalitytreatmentforantibodymediatedrejectionwithantihlaandantiat1rantibodiesafterkidneytransplantation |